- Teva Canada, a subsidiary of Teva Pharmaceutical (NYSE:TEVA) announces the availability of Aermony RespiClick, indicated for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older and offered in a simple-to-use inhaler.
- Aermony RespiClick (fluticasone propionate inhalation powder) is designed to simplify the administration of inhaled therapy and reduce patient error and confusion.
- Aermony RespiClick will come in three dose options: 55 mcg, 113 mcg and 232 mcg per actuation.
- Patients using Aermony RespiClick take one inhalation twice daily at the same time every day, approx. 12 hours apart.